

Per Soelberg SÃ¸rensen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3744973/publications.pdf>

Version: 2024-02-01

337
papers

34,965
citations

7568

77
h-index

4015

176
g-index

347
all docs

347
docs citations

347
times ranked

27936
citing authors

#	ARTICLE	IF	CITATIONS
1	Fitbeat: COVID-19 estimation based on wristband heart rate using a contrastive convolutional auto-encoder. Pattern Recognition, 2022, 123, 108403.	8.1	26
2	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. Multiple Sclerosis Journal, 2022, 28, 1424-1456.	3.0	16
3	Population Pharmacokinetic Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis. CNS Drugs, 2022, 36, 283-300.	5.9	15
4	Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis. CNS Drugs, 2022, 36, 569-589.	5.9	6
5	Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 188-197.	3.0	8
6	Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 556-562.	1.9	7
7	Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network. Frontiers in Neurology, 2021, 12, 647811.	2.4	17
8	Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network. Multiple Sclerosis Journal, 2021, 27, 1543-1555.	3.0	33
9	Age and sex as determinants of treatment decisions in patients with relapsing-remitting MS. Multiple Sclerosis and Related Disorders, 2021, 50, 102813.	2.0	7
10	Transcriptome and Function of Novel Immunosuppressive Autoreactive Invariant Natural Killer T Cells That Are Absent in Progressive Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, e1065.	6.0	1
11	The effectiveness of natalizumab vs fingolimod A comparison of international registry studies. Multiple Sclerosis and Related Disorders, 2021, 53, 103012.	2.0	8
12	Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	15
13	Relapses add to permanent disability in relapsing multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2021, 53, 103029.	2.0	5
14	Averting multiple sclerosis long-term societal and healthcare costs: The Value of Treatment (VoT) project. Multiple Sclerosis and Related Disorders, 2021, 54, 103107.	2.0	3
15	Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. Lancet Neurology, The, 2021, 20, 917-929.	10.2	42
16	Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110582.	3.5	9
17	Predictors of treatment outcome in patients with paediatric onset multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 964-975.	3.0	11
18	Effectiveness of glatiramer acetate in neutralizing antibody-positive patients previously treated with interferon-β. Multiple Sclerosis and Related Disorders, 2020, 39, 101894.	2.0	1

#	ARTICLE	IF	CITATIONS
19	Clinical characteristics and use of disease modifying therapy in the nationwide Danish cohort of paediatric onset multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101431.	2.0	6
20	Clinically stable disease is associated with a lower risk of both income loss and disability pension for patients with multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 67-74.	1.9	15
21	The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history. <i>Brain</i> , 2020, 143, 2637-2652.	7.6	56
22	Comorbidity in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2020, 11, 851.	2.4	89
23	The window of opportunity for treatment of progressive multiple sclerosis. <i>Current Opinion in Neurology</i> , 2020, 33, 262-270.	3.6	27
24	Aggressive multiple sclerosis (2): Treatment. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1045-1063.	3.0	21
25	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1031-1044.	3.0	39
26	Expert opinion on the use of cladribine tablets in clinical practice. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642093501.	3.5	23
27	Initial high-efficacy disease-modifying therapy in multiple sclerosis. <i>Neurology</i> , 2020, 95, e1041-e1051.	1.1	83
28	Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study. <i>Neurological Sciences</i> , 2020, 41, 1647-1650.	1.9	48
29	Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 40, 101956.	2.0	18
30	Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis. <i>CNS Drugs</i> , 2020, 34, 269-280.	5.9	49
31	Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing-Remitting Multiple Sclerosis Patients? A Narrative Review. <i>Neurology and Therapy</i> , 2020, 9, 55-66.	3.2	18
32	Using Smartphones and Wearable Devices to Monitor Behavioral Changes During COVID-19. <i>Journal of Medical Internet Research</i> , 2020, 22, e19992.	4.3	155
33	Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1298-1305.	3.0	24
34	Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1444-1451.	3.0	47
35	Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. <i>Science</i> , 2019, 365, .	12.6	710
36	Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 29, 168-174.	2.0	94

#	ARTICLE	IF	CITATIONS
37	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Lancet Neurology, The</i> , 2019, 18, 185-197.	10.2	110
38	MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. <i>Trials</i> , 2019, 20, 263.	1.6	58
39	Worsening of disability caused by relapses in multiple sclerosis: A different approach. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 32, 1-8.	2.0	28
40	Comparative effectiveness of teriflunomide and dimethyl fumarate. <i>Neurology</i> , 2019, 92, e1811-e1820.	1.1	36
41	Pulsed immune reconstitution therapy in multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2019, 12, 175628641983691.	3.5	54
42	The changing course of multiple sclerosis: rising incidence, change in geographic distribution, disease course, and prognosis. <i>Current Opinion in Neurology</i> , 2019, 32, 320-326.	3.6	60
43	Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. <i>Journal of Neuroimmunology</i> , 2019, 326, 19-27.	2.3	22
44	The Multiple Sclerosis Care Unit. <i>Multiple Sclerosis Journal</i> , 2019, 25, 627-636.	3.0	90
45	Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy. <i>Journal of Neurology</i> , 2019, 266, 306-315.	3.6	18
46	Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 819-827.	3.0	46
47	Progressive multiple sclerosis, cognitive function, and quality of life. <i>Brain and Behavior</i> , 2018, 8, e00875.	2.2	48
48	Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsingâremitting multiple sclerosis: the CLARITY Extension study. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628561775336.	3.5	45
49	ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 96-120.	3.0	458
50	Disability in progressive MS is associated with T2 lesion changes. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 73-77.	2.0	6
51	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. <i>Lancet Neurology, The</i> , 2018, 17, 162-173.	10.2	4,605
52	Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop. <i>Multiple Sclerosis Journal</i> , 2018, 24, 590-603.	3.0	101
53	Safety and efficacy of cladribine tablets in patients with relapsingâremitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1594-1604.	3.0	227
54	Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. <i>Cell</i> , 2018, 175, 1679-1687.e7.	28.9	115

#	ARTICLE	IF	CITATIONS
55	O39â€¦Rates of lymphopenia in years 1â€“4 in patients with relapsing multiple sclerosis treated annually with cladribine tablets. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A16.2-A16.	1.9	3
56	Early safety and efficacy of fingolimod treatment in Denmark. <i>Acta Neurologica Scandinavica</i> , 2017, 135, 129-133.	2.1	15
57	A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod. <i>Multiple Sclerosis Journal</i> , 2017, 23, 234-241.	3.0	38
58	Spinal cord atrophy in anterior-posterior direction reflects impairment in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2017, 136, 330-337.	2.1	8
59	Chronic comorbidity in multiple sclerosis is associated with lower incomes and dissolved intimate relationships. <i>European Journal of Neurology</i> , 2017, 24, 825-834.	3.3	21
60	Monoclonal Antibodies for Relapsing Multiple Sclerosis: A Review of Recently Marketed and Late-Stage Agents. <i>CNS Drugs</i> , 2017, 31, 357-371.	5.9	11
61	Defining active progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1727-1735.	3.0	34
62	Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality. <i>Neurology</i> , 2017, 89, 1668-1675.	1.1	57
63	Employment, disability pension and income for children with parental multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1148-1156.	3.0	9
64	High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial. <i>Multiple Sclerosis Journal</i> , 2017, 23, 675-685.	3.0	38
65	Safety concerns and risk management of multiple sclerosis therapies. <i>Acta Neurologica Scandinavica</i> , 2017, 136, 168-186.	2.1	65
66	Evolving concepts in the treatment of relapsing multiple sclerosis. <i>Lancet, The</i> , 2017, 389, 1347-1356.	13.7	252
67	Cell-based therapeutic strategies for multiple sclerosis. <i>Brain</i> , 2017, 140, 2776-2796.	7.6	139
68	Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results. <i>PLoS ONE</i> , 2017, 12, e0170395.	2.5	34
69	Laquinimod Safety Profile. <i>International Journal of MS Care</i> , 2017, 19, 16-24.	1.0	15
70	The Danish Multiple Sclerosis Treatment Register. <i>Clinical Epidemiology</i> , 2016, Volume 8, 549-552.	3.0	35
71	Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis. <i>PLoS ONE</i> , 2016, 11, e0162752.	2.5	41
72	Minocycline added to subcutaneous interferon Î²â€“1a in multiple sclerosis: randomized <sc>RECYCLINE</sc> study. <i>European Journal of Neurology</i> , 2016, 23, 861-870.	3.3	41

#	ARTICLE	IF	CITATIONS
73	Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1386-1396.	3.0	118
74	Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine. <i>Multiple Sclerosis Journal</i> , 2016, 22, 944-954.	3.0	21
75	Educational achievements of children of parents with multiple sclerosis: A nationwide register-based cohort study. <i>Journal of Neurology</i> , 2016, 263, 2229-2237.	3.6	10
76	Vascular comorbidities in multiple sclerosis: a nationwide study from Denmark. <i>Journal of Neurology</i> , 2016, 263, 2484-2493.	3.6	40
77	Haematopoietic stem cell transplants should be a second-line therapy for highly active MS – NO. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1260-1263.	3.0	4
78	Neurofilament in CSF – A biomarker of disease activity and long-term prognosis in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1112-1113.	3.0	15
79	Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 10, 169-173.	2.0	68
80	Inverse comorbidity in multiple sclerosis: Findings in a complete nationwide cohort. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 10, 181-186.	2.0	16
81	NR1H3 p.Arg415Gln Is Not Associated to Multiple Sclerosis Risk. <i>Neuron</i> , 2016, 92, 333-335.	8.1	24
82	Recovery from an acute relapse is associated with changes in motor resting-state connectivity in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 912-914.	1.9	8
83	Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta. <i>Journal of Immunological Methods</i> , 2016, 430, 1-9.	1.4	18
84	Generic glatiramer acetate – a step toward cheaper MS drugs?. <i>Nature Reviews Neurology</i> , 2016, 12, 5-6.	10.1	6
85	Ozanimod: a better or just another S1P receptor modulator?. <i>Lancet Neurology</i> , The, 2016, 15, 345-347.	10.2	11
86	Cytokine profiles show heterogeneity of interferon- β response in multiple sclerosis patients. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e202.	6.0	34
87	The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects. <i>Therapeutic Advances in Neurological Disorders</i> , 2016, 9, 44-52.	3.5	103
88	Association between age at onset of multiple sclerosis and vitamin D level – related factors. <i>Neurology</i> , 2016, 86, 88-93.	1.1	28
89	Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 926-934.	3.0	23
90	Endogenous Interferon- β -Inducible Gene Expression and Interferon- β -Treatment Are Associated with Reduced T Cell Responses to Myelin Basic Protein in Multiple Sclerosis. <i>PLoS ONE</i> , 2015, 10, e0118830.	2.5	18

#	ARTICLE	IF	CITATIONS
91	Genetic and environmental determinants of 25-hydroxyvitamin D levels in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1414-1422.	3.0	18
92	A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview. <i>Multiple Sclerosis Journal</i> , 2015, 21, 263-281.	3.0	273
93	The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review. <i>Multiple Sclerosis Journal</i> , 2015, 21, 305-317.	3.0	381
94	Short-term, high-dose glucocorticoid treatment does not contribute to reduced bone mineral density in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1557-1565.	3.0	17
95	<i>Trichuris suis</i> ova therapy in relapsing multiple sclerosis is safe but without signals of beneficial effect. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1723-1729.	3.0	56
96	Therapeutic interference with leukocyte recirculation in multiple sclerosis. <i>European Journal of Neurology</i> , 2015, 22, 434-442.	3.3	9
97	Factors influencing success of clinical genome sequencing across a broad spectrum of disorders. <i>Nature Genetics</i> , 2015, 47, 717-726.	21.4	310
98	The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: A systematic review. <i>Multiple Sclerosis Journal</i> , 2015, 21, 332-341.	3.0	39
99	A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 282-293.	3.0	131
100	A systematic review of the incidence and prevalence of cancer in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 294-304.	3.0	79
101	A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 342-349.	3.0	100
102	A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 318-331.	3.0	131
103	Secondary Progressive and Relapsing Remitting Multiple Sclerosis Leads to Motor-Related Decreased Anatomical Connectivity. <i>PLoS ONE</i> , 2014, 9, e95540.	2.5	17
104	Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development. <i>Multiple Sclerosis Journal</i> , 2014, 20, 577-587.	3.0	40
105	Cortical N-acetyl aspartate is a predictor of long-term clinical disability in multiple sclerosis. <i>Neurological Research</i> , 2014, 36, 701-708.	1.3	9
106	Prediction of response to interferon therapy in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2014, 130, 268-275.	2.1	21
107	The chemokine receptor CCR5 $\Delta 32$ allele in natalizumab-treated multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2014, 129, 27-31.	2.1	9
108	Gender effects on treatment response to interferon-beta in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2014, 130, 374-379.	2.1	15

#	ARTICLE	IF	CITATIONS
109	New management algorithms in multiple sclerosis. <i>Current Opinion in Neurology</i> , 2014, 27, 246-259.	3.6	95
110	Gender and autoimmune comorbidity in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1244-1251.	3.0	28
111	Effects of fingolimod in relapsing-remitting multiple sclerosis. <i>Lancet Neurology</i> , The, 2014, 13, 526-527.	10.2	7
112	FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS. <i>Nature Medicine</i> , 2014, 20, 272-282.	30.7	141
113	A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. <i>Journal of Neurology</i> , 2014, 261, 773-783.	3.6	168
114	Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. <i>Journal of Neurology</i> , 2014, 261, 1170-1177.	3.6	127
115	Immunological effects of methylprednisolone pulse treatment in progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2014, 276, 195-201.	2.3	8
116	Gene expression in smoking and non-smoking patients with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2014, 275, 49.	2.3	1
117	Physical and social environment and the risk of multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 600-606.	2.0	21
118	Defining the clinical course of multiple sclerosis. <i>Neurology</i> , 2014, 83, 278-286.	1.1	2,344
119	Multiple sclerosis impairs regional functional connectivity in the cerebellum. <i>NeuroImage: Clinical</i> , 2014, 4, 130-138.	2.7	42
120	Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 179-187.	3.0	27
121	MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. <i>Journal of Neurology</i> , 2013, 260, 1136-1146.	3.6	46
122	Differential microRNA expression in blood in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1849-1857.	3.0	110
123	Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. <i>Nature Genetics</i> , 2013, 45, 1353-1360.	21.4	1,213
124	Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1841-1848.	3.0	29
125	Preserved in vivo response to interferon-alpha in multiple sclerosis patients with neutralising antibodies against interferon-beta (REPAIR study). <i>Multiple Sclerosis and Related Disorders</i> , 2013, 2, 141-146.	2.0	6
126	Resting-state connectivity of pre-motor cortex reflects disability in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2013, 128, n/a-n/a.	2.1	33

#	ARTICLE	IF	CITATIONS
127	Expanded functional coupling of subcortical nuclei with the motor resting-state network in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 559-566.	3.0	39
128	Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1226-1229.	3.0	18
129	Reproduction and the risk of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1604-1609.	3.0	54
130	Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1533-1538.	3.0	92
131	CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 877-884.	3.0	75
132	Prolonged-release fampridine improves walking in a proportion of patients with multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 1309-1317.	2.8	5
133	Systemic Inflammation in Progressive Multiple Sclerosis Involves Follicular T-Helper, Th17- and Activated B-Cells and Correlates with Progression. <i>PLoS ONE</i> , 2013, 8, e57820.	2.5	213
134	Multiple Sclerosis Management – A Changing Landscape 2013. <i>European Neurological Review</i> , 2013, 8, 105.	0.5	0
135	Prediction of antibody persistency from antibody titres to natalizumab. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1493-1499.	3.0	21
136	Effects of neutralizing antibodies to interferon beta in multiple sclerosis: a logical paradox. <i>Multiple Sclerosis Journal</i> , 2012, 18, 131-132.	3.0	6
137	Deaths and disability from natalizumab are no longer tolerable: No – (they can be avoided). <i>Multiple Sclerosis Journal</i> , 2012, 18, 1070-1072.	3.0	2
138	Glatiramer acetate antibodies, gene expression and disease activity in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 305-313.	3.0	21
139	Cerebral metabolism, magnetic resonance spectroscopy and cognitive dysfunction in early multiple sclerosis: an exploratory study. <i>Neurological Research</i> , 2012, 34, 52-58.	1.3	11
140	<i>FOXP3</i> , <i>CCL4</i> and <i>ITCH</i> gene expression and cytotoxic T lymphocyte antigen 4 expression on CD4+CD25 ^{high} T cells in multiple sclerosis. <i>Clinical and Experimental Immunology</i> , 2012, 170, 149-155.	2.6	34
141	Association between DPP6 polymorphism and the risk of progressive multiple sclerosis in Northern and Southern Europeans. <i>Neuroscience Letters</i> , 2012, 530, 155-160.	2.1	17
142	Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. <i>Multiple Sclerosis Journal</i> , 2012, 18, 143-152.	3.0	220
143	Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2012, 9, 215.	7.2	66
144	Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis. <i>Clinical Drug Investigation</i> , 2012, 32, 15-27.	2.2	11

#	ARTICLE	IF	CITATIONS
145	Endogenous and Recombinant Type I Interferons and Disease Activity in Multiple Sclerosis. PLoS ONE, 2012, 7, e35927.	2.5	14
146	Effect of Natalizumab on Circulating CD4+ T-Cells in Multiple Sclerosis. PLoS ONE, 2012, 7, e47578.	2.5	59
147	Cognitive deficits in multiple sclerosis: correlations with T2 changes in normal appearing brain tissue. Acta Neurologica Scandinavica, 2012, 125, 338-344.	2.1	18
148	Chronic cerebrospinal venous insufficiency and venous stenoses in multiple sclerosis. Acta Neurologica Scandinavica, 2012, 126, 421-427.	2.1	34
149	Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study. Multiple Sclerosis and Related Disorders, 2012, 1, 49-54.	2.0	29
150	Correlation between anti-interferon- β binding and neutralizing antibodies in interferon- β treated multiple sclerosis patients. European Journal of Neurology, 2012, 19, 1311-1317.	3.3	15
151	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature, 2011, 476, 214-219.	27.8	2,400
152	Why does the north-south gradient of incidence of multiple sclerosis seem to have disappeared on the Northern hemisphere?. Journal of the Neurological Sciences, 2011, 311, 58-63.	0.6	63
153	Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis. Journal of the Neurological Sciences, 2011, 311, S29-S34.	0.6	15
154	Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLADribine Tablets) Trial. <i>Journal of Neurology</i> , 2011, 250, 1099-1109.	3.0	109
155	Cladribine in the treatment of multiple sclerosis. Clinical Investigation, 2011, 1, 317-326.	0.0	3
156	Disease protection and interleukin-10 induction by endogenous interferon- β in multiple sclerosis?. European Journal of Neurology, 2011, 18, 266-272.	3.3	40
157	Alterations in KLRB1 gene expression and a Scandinavian multiple sclerosis association study of the KLRB1 SNP rs4763655. European Journal of Human Genetics, 2011, 19, 1100-1103.	2.8	9
158	Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurology, The, 2011, 10, 329-337.	10.2	199
159	Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. Lancet Neurology, The, 2011, 10, 691-701.	10.2	114
160	Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurology, The, 2011, 10, 745-758.	10.2	247
161	Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. Multiple Sclerosis Journal, 2011, 17, 1074-1078.	3.0	50
162	Neutralizing antibodies against interferon- β do not predispose antibodies against natalizumab. Neurology, 2011, 76, 759-760.	1.1	14

#	ARTICLE	IF	CITATIONS
163	Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011, 17, 32-42.	3.0	64
164	Principles of a new treatment algorithm in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 351-362.	2.8	23
165	The changing demographic pattern of multiple sclerosis epidemiology. <i>Lancet Neurology</i> , The, 2010, 9, 520-532.	10.2	914
166	Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. <i>Lancet Neurology</i> , The, 2010, 9, 740-750.	10.2	188
167	Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. <i>Lancet Neurology</i> , The, 2010, 9, 672-680.	10.2	70
168	EFNS guidelines on diagnosis and management of neuromyelitis optica. <i>European Journal of Neurology</i> , 2010, 17, 1019-1032.	3.3	376
169	Genetic variants of CC chemokine genes in experimental autoimmune encephalomyelitis, multiple sclerosis and rheumatoid arthritis. <i>Genes and Immunity</i> , 2010, 11, 142-154.	4.1	23
170	Demyelination versus remyelination in progressive multiple sclerosis. <i>Brain</i> , 2010, 133, 2983-2998.	7.6	261
171	A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2010, 362, 416-426.	27.0	791
172	Polymorphisms of innate pattern recognition receptors, response to interferon-beta and development of neutralizing antibodies in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2010, 16, 942-949.	3.0	29
173	Effects of infectious mononucleosis and HLA-DRB1*15 in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 431-436.	3.0	88
174	Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 323-328.	3.0	21
175	The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 601-605.	3.0	23
176	The relation between inflammation and neurodegeneration in multiple sclerosis brains. <i>Brain</i> , 2009, 132, 1175-1189.	7.6	1,182
177	Multiple sclerosis and polymorphisms of innate pattern recognition receptors TLR1-10, NOD1-2, DDX58, and IFIH1. <i>Journal of Neuroimmunology</i> , 2009, 212, 125-131.	2.3	65
178	Comparison of clinical neurological function and CT response during chemotherapy for initial brain metastases from small cell lung cancer. <i>Acta Neurologica Scandinavica</i> , 2009, 89, 372-377.	2.1	2
179	NORDic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2009, 8, 519-529.	10.2	95
180	Autoantibodies to myelin basic protein (MBP) in healthy individuals and in patients with multiple sclerosis: a role in regulating cytokine responses to MBP. <i>Immunology</i> , 2009, 128, e451-61.	4.4	55

#	ARTICLE	IF	CITATIONS
181	Management of patients with neutralizing antibodies against interferon-β: stop IFN-β therapy or wait for the antibodies to go away?. European Journal of Neurology, 2009, 16, 1-2.	3.3	7
182	Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon-β. European Journal of Neurology, 2009, 16, 43-47.	3.3	25
183	Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. European Journal of Neurology, 2009, 16, 420-423.	3.3	84
184	How effective is natalizumab as second-line treatment for multiple sclerosis in daily clinical praxis?. European Journal of Neurology, 2009, 16, 287-288.	3.3	1
185	Identification of new sensitive biomarkers for the <i>in vivo</i> response to interferon-β treatment in multiple sclerosis using DNA-array evaluation. European Journal of Neurology, 2009, 16, 1291-1298.	3.3	50
186	Safety and immunogenicity of a new formulation of interferon-β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Multiple Sclerosis Journal, 2009, 15, 219-228.	3.0	67
187	The SH2D2A Gene -Contributions to Our Future Understanding of Multiple Sclerosis. European Neurological Review, 2009, 4, 68.	0.5	0
188	Editorial. Journal of Neurology, 2008, 255, 1-2.	3.6	0
189	EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases. European Journal of Neurology, 2008, 15, 893-908.	3.3	272
190	The effect of β-interferon therapy on myelin basic protein-elicited CD4+ T cell proliferation and cytokine production in multiple sclerosis. Clinical Immunology, 2008, 129, 80-89.	3.2	14
191	REGARD: what can we learn from randomised, open-label, head-to-head studies?. Lancet Neurology, The, 2008, 7, 864-866.	10.2	4
192	The SH2D2A gene and susceptibility to multiple sclerosis. Journal of Neuroimmunology, 2008, 197, 152-158.	2.3	14
193	Intravenous Polyclonal Human Immunoglobulins in Multiple Sclerosis. Neurodegenerative Diseases, 2008, 5, 8-15.	1.4	15
194	447: Remyelination is extensive in a subset of multiple sclerosis patients. Journal of Clinical Neuroscience, 2008, 15, 358.	1.5	0
195	Oral fumarate for relapsing-remitting multiple sclerosis. Lancet, The, 2008, 372, 1447-1448.	13.7	7
196	Gene expression analysis of interferon-β treatment in multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 615-621.	3.0	35
197	Review: Neutralizing antibodies against interferon-beta. Therapeutic Advances in Neurological Disorders, 2008, 1, 125-141.	3.5	33
198	Can we spot the IFN-β nonresponders?. Neurology, 2008, 71, 1936-1937.	1.1	2

#	ARTICLE	IF	CITATIONS
199	Is the treatment effect of IFN- \hat{I}^2 restored after the disappearance of neutralizing antibodies?. Multiple Sclerosis Journal, 2008, 14, 837-842.	3.0	23
200	Fatal neurogenic pulmonary edema in a patient with progressive multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 711-715.	3.0	19
201	Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon- \hat{I}^2 treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression. Multiple Sclerosis Journal, 2008, 14, 622-630.	3.0	64
202	Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. Journal of International Medical Research, 2008, 36, 204-8; author reply 208-10.	1.0	3
203	Health-related quality of life in secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 2007, 13, 386-392.	3.0	46
204	Multiple Sclerosis After Infectious Mononucleosis. Archives of Neurology, 2007, 64, 72.	4.5	170
205	Are ex vivo neutralising antibodies against IFN- \hat{I}^2 always detrimental to therapeutic efficacy in multiple sclerosis?. Multiple Sclerosis Journal, 2007, 13, 616-621.	3.0	38
206	Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology, 2007, 69, 1552-1553.	1.1	11
207	Immunogenicity and tolerability of an investigational formulation of interferon- \hat{I}^2 1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis. Clinical Therapeutics, 2007, 29, 1128-1145.	2.5	38
208	A follow-up study of Nordic multiple sclerosis candidate gene regions. Multiple Sclerosis Journal, 2007, 13, 584-589.	3.0	0
209	The gap between effect of drugs and effectiveness of treatments. Journal of the Neurological Sciences, 2007, 259, 128-132.	0.6	4
210	Widespread Demyelination in the Cerebellar Cortex in Multiple Sclerosis. Brain Pathology, 2007, 17, 38-44.	4.1	301
211	Using measurements of neutralizing antibodies: the challenge of IFN- \hat{I}^2 therapy. European Journal of Neurology, 2007, 14, 850-859.	3.3	43
212	Resource allocation to brain research in Europe. European Journal of Neurology, 2007, 14, 597-597.	3.3	0
213	IVIg enters the central nervous system during treatment of experimental autoimmune encephalomyelitis and is localised to inflammatory lesions. Experimental Brain Research, 2007, 178, 462-469.	1.5	18
214	Neutralising antibodies to interferon \hat{I}^2 in multiple sclerosis. Journal of Neurology, 2007, 254, 827-837.	3.6	48
215	Cognitive impairment in newly diagnosed multiple sclerosis patients: A 4-year follow-up study. Journal of the Neurological Sciences, 2006, 245, 77-85.	0.6	75
216	The relationship between MRI and PET changes and cognitive disturbances in MS. Journal of the Neurological Sciences, 2006, 245, 99-102.	0.6	17

#	ARTICLE	IF	CITATIONS
217	A prospective PET study of patients with glioblastoma multiforme. <i>Acta Neurologica Scandinavica</i> , 2006, 113, 412-418.	2.1	2
218	Dynamic Tâ€lymphocyte Chemokine Receptor Expression Induced by Interferonâ€beta Therapy in Multiple Sclerosis. <i>Scandinavian Journal of Immunology</i> , 2006, 64, 155-163.	2.7	26
219	Neutralising antibodies to interferon-Î²â€ measurement, clinical relevance, and management. <i>Journal of Neurology</i> , 2006, 253, vi16-vi22.	3.6	2
220	CD4+ memory T cells with high CD26 surface expression are enriched for Th1 markers and correlate with clinical severity of multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2006, 181, 157-164.	2.3	51
221	Remyelination is extensive in a subset of multiple sclerosis patients. <i>Brain</i> , 2006, 129, 3165-3172.	7.6	667
222	Correlation of Global N-Acetyl Aspartate With Cognitive Impairment in Multiple Sclerosis. <i>Archives of Neurology</i> , 2006, 63, 533.	4.5	61
223	Neutralizing antibodies hamper IFNÎ² bioactivity and treatment effect on MRI in patients with MS. <i>Neurology</i> , 2006, 67, 1681-1683.	1.1	60
224	The efficacy of multidisciplinary rehabilitation in stable multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2006, 12, 235-242.	3.0	65
225	Measuring and evaluating interferon b-induced antibodies in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2006, 12, 39-46.	3.0	35
226	Persistence of neutralizing antibodies after discontinuation of IFNÎ² therapy in patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2006, 12, 247-252.	3.0	51
227	Immunomodulatory treatment of multiple sclerosis in Denmark: a prospective nationwide survey. <i>Multiple Sclerosis Journal</i> , 2006, 12, 253-264.	3.0	28
228	The Six Spot Step Test: a new measurement for walking ability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2006, 12, 495-500.	3.0	104
229	EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. <i>European Journal of Neurology</i> , 2005, 12, 939-946.	3.3	123
230	Guidelines on use of antiâ€IFNâ€ antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFNâ€ antibodies in multiple sclerosis. <i>European Journal of Neurology</i> , 2005, 12, 817-827.	3.3	226
231	Multiple sclerosis: pathophysiology revisited. <i>Lancet Neurology</i> , The, 2005, 4, 9-10.	10.2	14
232	Multi-slice echo-planar spectroscopic MR imaging provides both global and local metabolite measures in multiple sclerosis. <i>Magnetic Resonance in Medicine</i> , 2005, 53, 750-759.	3.0	25
233	Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. <i>Neurology</i> , 2005, 65, 33-39.	1.1	190
234	Therapeutic Considerations for Disease Progression in Multiple Sclerosis. <i>Archives of Neurology</i> , 2005, 62, 1519-30.	4.5	36

#	ARTICLE	IF	CITATIONS
235	CD26+CD4+T cell counts and attack risk in interferon-treated multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2005, 11, 641-645.	3.0	14
236	Intravenous immunoglobulin ameliorates experimental autoimmune encephalomyelitis and reduces neuropathological abnormalities when administered prophylactically. <i>Neurological Research</i> , 2005, 27, 591-597.	1.3	20
237	Responsiveness of the Multiple Sclerosis Impairment Scale in comparison with the Expanded Disability Status Scale. <i>Multiple Sclerosis Journal</i> , 2005, 11, 81-84.	3.0	30
238	MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS). <i>Multiple Sclerosis Journal</i> , 2005, 11, 433-440.	3.0	47
239	Intravenous immunoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis. <i>Journal of the Neurological Sciences</i> , 2005, 233, 61-65.	0.6	41
240	Concordance for disease course and age of onset in Scandinavian multiple sclerosis coaffected sib pairs. <i>Multiple Sclerosis Journal</i> , 2004, 10, 5-8.	3.0	24
241	IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. <i>Neurology</i> , 2004, 63, 2028-2033.	1.1	107
242	Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis. <i>Tissue Antigens</i> , 2004, 63, 237-247.	1.0	130
243	Early-Stage Multiple Sclerosis. <i>Drugs</i> , 2004, 64, 2021-2029.	10.9	1
244	Significantly increased fractions of transformed to total $\hat{I}2$ -macroglobulin concentrations in plasma from patients with multiple sclerosis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2004, 1690, 203-207.	3.8	17
245	Neutralising antibodies against interferon beta in multiple sclerosis. <i>Lancet, The</i> , 2004, 363, 168-169.	13.7	3
246	Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. <i>Lancet, The</i> , 2004, 364, 1149-1156.	13.7	181
247	Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis. <i>Neurology</i> , 2004, 63, S42-9.	1.1	23
248	Association between an interleukin $\hat{I}3$ promoter polymorphism and atopy. <i>International Journal of Immunogenetics</i> , 2003, 30, 355-359.	1.2	73
249	Two genome-wide linkage disequilibrium screens in Scandinavian multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2003, 143, 101-106.	2.3	15
250	Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon $\hat{I}21a$. <i>Annals of Neurology</i> , 2003, 53, 718-724.	5.3	120
251	The role of intravenous immunoglobulin in the treatment of multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2003, 206, 123-130.	0.6	32
252	Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. <i>Lancet, The</i> , 2003, 362, 1184-1191.	13.7	366

#	ARTICLE	IF	CITATIONS
253	Risk Factors for Acute Respiratory Tract Infections in Young Greenlandic Children. American Journal of Epidemiology, 2003, 158, 374-384.	3.4	98
254	Antibodies to IFN-beta. Neurology, 2003, 61, S27-8.	1.1	8
255	Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRB1*1501, CCR5 deletion mutation, apolipoprotein E). Multiple Sclerosis Journal, 2002, 8, 295-298.	3.0	55
256	Population-Based Study of Acute Respiratory Infections in Children, Greenland. Emerging Infectious Diseases, 2002, 8, 586-593.	4.3	57
257	Reporting clinical trials: full access to all the data. European Journal of Neurology, 2002, 9, 123-124.	3.3	4
258	Intravenous immunoglobulin G for the treatment of relapsing–remitting multiple sclerosis: a meta–analysis. European Journal of Neurology, 2002, 9, 557-563.	3.3	121
259	A genome-wide screen for linkage in Nordic sib-pairs with multiple sclerosis. Genes and Immunity, 2002, 3, 279-285.	4.1	73
260	Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet, The, 2001, 357, 1576-1582.	13.7	1,025
261	Correlations of brain MRI parameters to disability in multiple sclerosis. Acta Neurologica Scandinavica, 2001, 104, 24-30.	2.1	37
262	The T cell regulator gene SH2D2A contributes to the genetic susceptibility of multiple sclerosis. Genes and Immunity, 2001, 2, 263-268.	4.1	44
263	Linkage analysis suggests a region of importance for multiple sclerosis in 3p14–13. Genes and Immunity, 2001, 2, 451-454.	4.1	4
264	No linkage or association of the nitric oxide synthase genes to multiple sclerosis. Journal of Neuroimmunology, 2001, 119, 95-100.	2.3	18
265	Acute Respiratory Tract Infections and Mannose-Binding Lectin Insufficiency During Early Childhood. JAMA - Journal of the American Medical Association, 2001, 285, 1316.	7.4	381
266	Immunogenicity of interferon-? in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration. Annals of Neurology, 2000, 48, 706-712.	5.3	224
267	A new millennium? Perhaps. A new European Journal of Neurology? Certainly!. European Journal of Neurology, 2000, 7, 1-1.	3.3	2
268	Prognostic factors in metastatic spinal cord compression: a prospective study using multivariate analysis of variables influencing survival and gait function in 153 patients. International Journal of Radiation Oncology Biology Physics, 2000, 46, 1163-1169.	0.8	231
269	Linkage analysis of a candidate region in Scandinavian sib pairs with multiple sclerosis reveals linkage to chromosome 17q. Genes and Immunity, 2000, 1, 456-459.	4.1	29
270	Correlates of heterosexual behavior among 23-87 year olds in Denmark and Sweden, 1992-1998. Archives of Sexual Behavior, 2000, 29, 91-106.	1.9	20

#	ARTICLE	IF	CITATIONS
271	The Effect on MRI of Gammaglobulin Treatment in Relapsing Multiple Sclerosis. <i>Multiple Sclerosis Journal</i> , 2000, 6, S14-S17.	3.0	1
272	Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. <i>Lancet, The</i> , 2000, 355, 2189-2193.	13.7	338
273	Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. <i>Lancet, The</i> , 2000, 355, 2194-2198.	13.7	295
274	Intravenous Immunoglobulin Treatment in Neurologic Disorders. <i>Archives of Neurology</i> , 1999, 56, 1025.	4.5	6
275	Smoking and oral contraceptives as risk factors for cervical carcinoma in situ. , 1999, 81, 357-365.		91
276	Radiologic features compared to clinical findings in a prospective study of 153 patients with metastatic spinal cord compression treated by radiotherapy. <i>Acta Neurochirurgica</i> , 1997, 139, 105-111.	1.7	19
277	Intravenous immunoglobulin G therapy: effects of acute and chronic treatment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 1996, 1, 349-352.	3.0	6
278	Sumatriptan has no clinically relevant effect in the treatment of episodic tension-type headache. <i>European Journal of Neurology</i> , 1996, 3, 23-28.	3.3	63
279	Central motor conduction as a measure of disease progression in early multiple sclerosis. <i>European Journal of Neurology</i> , 1995, 1, 233-241.	3.3	2
280	Second occurrence of symptomatic metastatic spinal cord compression and findings of multiple spinal epidural metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995, 33, 595-598.	0.8	46
281	Cerebrospinal fluid flow and production in patients with normal pressure hydrocephalus studied by MRI. <i>Neuroradiology</i> , 1994, 36, 210-215.	2.2	114
282	Assessment of CSF dynamics and venous flow in the superior sagittal sinus by MRI in idiopathic intracranial hypertension: a preliminary study. <i>Neuroradiology</i> , 1994, 36, 350-354.	2.2	52
283	Symptoms and signs in metastatic spinal cord compression: a study of progression from first symptom until diagnosis in 153 patients. <i>European Journal of Cancer</i> , 1994, 30, 396-398.	2.8	224
284	Tolfenamic acid versus propranolol in the prophylactic treatment of migraine. <i>Acta Neurologica Scandinavica</i> , 1994, 89, 446-450.	2.1	10
285	Comparison of myelography combined with postmyelographic spinal CT and MRI in suspected metastatic disease of the spinal canal. <i>Journal of Neuro-Oncology</i> , 1992, 13, 231-7.	2.9	23
286	Flunarizine Versus Metoprolol in Migraine Prophylaxis: A Double-Blind, Randomized Parallel Group Study of Efficacy and Tolerability. <i>Headache</i> , 1991, 31, 650-657.	3.9	68
287	Intracranial pressure and cerebrospinal fluid outflow conductance in healthy subjects. <i>Journal of Neurosurgery</i> , 1991, 74, 597-600.	1.6	162
288	Carotid artery disease and low cerebral perfusion pressure: symptomatology, operative risk and outcome. <i>Neurological Research</i> , 1990, 12, 35-40.	1.3	2

#	ARTICLE	IF	CITATIONS
289	Metastatic spinal cord compression. <i>Acta Neurochirurgica</i> , 1990, 107, 37-43.	1.7	347
290	Sexual dysfunction in male and female patients with epilepsy: A study of 86 outpatients. <i>Archives of Sexual Behavior</i> , 1990, 19, 1-14.	1.9	79
291	Metastatic epidural spinal cord compression. Results of treatment and survival. <i>Cancer</i> , 1990, 65, 1502-1508.	4.1	209
292	Long-term prognosis and quality of life after reversible cerebral ischemic attacks. <i>Acta Neurologica Scandinavica</i> , 1989, 79, 204-213.	2.1	32
293	Prophylactic Effect of Flunarizine versus Metoprolol in Migraine. <i>Cephalalgia</i> , 1989, 9, 355-356.	3.9	5
294	Clinical course and prognosis of pseudotumor cerebri. A prospective study of 24 patients. <i>Acta Neurologica Scandinavica</i> , 1988, 77, 164-172.	2.1	71
295	Do concentrations of neurotransmitters measured in lumbar cerebrospinal fluid reflect the concentrations at brain level?. <i>Acta Neurochirurgica</i> , 1988, 91, 55-59.	1.7	25
296	Stroke incidence and risk factors for stroke in Copenhagen, Denmark.. <i>Stroke</i> , 1988, 19, 1345-1353.	2.0	235
297	Danish very-low-dose aspirin after carotid endarterectomy trial.. <i>Stroke</i> , 1988, 19, 1211-1215.	2.0	112
298	CSFâ€amine metabolites in depression, dementia and in controls. <i>Acta Psychiatrica Scandinavica</i> , 1987, 75, 619-628.	4.5	34
299	Intracerebral haemorrhage after carotid endarterectomy. <i>European Journal of Vascular Surgery</i> , 1987, 1, 51-60.	0.9	77
300	Cerebral blood flow in patients with normal-pressure hydrocephalus before and after shunting. <i>Journal of Neurosurgery</i> , 1987, 66, 379-387.	1.6	92
301	Absence of hydrocephalus in spite of impaired cerebrospinal fluid absorption and severe intracranial hypertension. <i>Acta Neurochirurgica</i> , 1987, 86, 93-97.	1.7	31
302	Resistance to cerebrospinal fluid outflow and intracranial pressure in patients with hydrocephales after subarachnoid haemorrhage. <i>Acta Neurochirurgica</i> , 1987, 88, 79-86.	1.7	57
303	Cerebrospinal fluid bombesin and calcitonin in patients with central nervous system metastases from small-cell lung cancer.. <i>Journal of Clinical Oncology</i> , 1986, 4, 1620-1627.	1.6	27
304	A Placebo-Controlled, Double-Blind, Cross-Over Trial of Flunarizine in Common Migraine. <i>Cephalalgia</i> , 1986, 6, 7-14.	3.9	84
305	Studies of vasopressin in the human cerebrospinal fluid. <i>Acta Neurologica Scandinavica</i> , 1986, 74, 81-102.	2.1	42
306	Motor Disturbances in Normal-Pressure Hydrocephalus. <i>Archives of Neurology</i> , 1986, 43, 34.	4.5	86

#	ARTICLE	IF	CITATIONS
307	Endocrine Studies in Patients With Pseudotumor Cerebri. Archives of Neurology, 1986, 43, 902.	4.5	54
308	Persistent disturbances of cognitive functions in patients with pseudotumor cerebri. Acta Neurologica Scandinavica, 1986, 73, 264-268.	2.1	41
309	Severe headache as the only symptom of long-standing shunt dysfunction in hydrocephalic children with normal or slit ventricles revealed by computed tomography. Child's Nervous System, 1985, 1, 49-52.	1.1	26
310	Cerebrospinal fluid and plasma vasopressin during short-time induced intracranial hypertension. Acta Neurochirurgica, 1985, 77, 46-51.	1.7	10
311	Cerebrospinal fluid vasopressin as a marker of central nervous system metastases from small-cell bronchogenic carcinoma.. Journal of Clinical Oncology, 1985, 3, 48-53.	1.6	16
312	Visual Evoked Potentials in Pseudotumor Cerebri. Archives of Neurology, 1985, 42, 150-153.	4.5	38
313	24-hour cerebrospinal fluid levels of vasopressin in hydrocephalic patients. Regulatory Peptides, 1985, 10, 115-126.	1.9	9
314	High cerebrospinal fluid concentration of glial fibrillary acidic protein (GFAP) in patients with normal pressure hydrocephalus. Journal of the Neurological Sciences, 1985, 70, 269-274.	0.6	49
315	Cardiac Disease in Patients with Reversible Cerebral Ischemic Events. Acta Medica Scandinavica, 1985, 217, 417-421.	0.0	2
316	Ophthalmologic prognosis in Benign Intracranial Hypertension. Acta Ophthalmologica, 1985, 63, 62-64.	1.1	9
317	Bone lesions in early syphilis detected by bone scintigraphy.. Sexually Transmitted Infections, 1984, 60, 265-268.	1.9	11
318	Impermeability of the blood-cerebrospinal fluid barrier to L-arginine vasopressin (DDAVP) in patients with acquired, communicating hydrocephalus. European Journal of Clinical Investigation, 1984, 14, 435-439.	3.4	39
319	Cerebrospinal fluid vasopressin and increased intracranial pressure. Annals of Neurology, 1984, 15, 435-440.	5.3	46
320	Effects of long-term carbamazepine treatment on water metabolism and plasma vasopressin concentration. European Journal of Clinical Pharmacology, 1984, 26, 719-722.	1.9	23
321	Plasma Vasopressin, Cortisol, and Growth Hormone Concentrations in Relation to Surgery in the Suprasellar Region. Acta Medica Scandinavica, 1984, 216, 31-39.	0.0	2
322	Prevalence of Mitral Valve Prolapse in Younger Patients with Cerebral Ischaemic Attacks. Acta Medica Scandinavica, 1984, 216, 385-391.	0.0	18
323	Low cerebrospinal fluid concentration of brain-specific protein D2 in patients with normal pressure hydrocephalus. Journal of the Neurological Sciences, 1983, 62, 59-65.	0.6	29
324	Prognostic Value of in vitro Measurements of Platelet Aggregability and Fibrinolytic Activity in Patients with Reversible Cerebral Ischemic Attacks. European Neurology, 1983, 22, 437-441.	1.4	9

#	ARTICLE	IF	CITATIONS
325	A Case of Malignant Lymphoma and Myasthenia Gravis. <i>Scandinavian Journal of Haematology</i> , 1983, 31, 155-160.	0.0	11
326	Vasopressin release during electroconvulsive therapy. <i>Psychoneuroendocrinology</i> , 1982, 7, 303-308.	2.7	15
327	Vasopressin in the cerebrospinal fluid of patients with normal pressure hydrocephalus and benign intracranial hypertension. <i>European Journal of Endocrinology</i> , 1982, 100, 211-215.	3.7	31
328	Prevalence of stroke in a district of Copenhagen. <i>Acta Neurologica Scandinavica</i> , 1982, 66, 68-81.	2.1	61
329	Electroconvulsive therapy: A comparison of seizure duration as monitored with electroencephalograph and electromyograph. <i>Acta Psychiatrica Scandinavica</i> , 1981, 64, 193-198.	4.5	12
330	Essential tremor treated with propranolol: Lack of correlation between clinical effect and plasma propranolol levels. <i>Annals of Neurology</i> , 1981, 9, 53-57.	5.3	25
331	Long-term prognosis after transient ischemic attacks. <i>Acta Neurologica Scandinavica</i> , 1981, 63, 156-168.	2.1	42
332	The incidence and clinical presentation of neurosyphilis in Greater Copenhagen 1974 through 1978. <i>Acta Neurologica Scandinavica</i> , 1981, 63, 237-246.	2.1	15
333	Elektromyografisk monitorering ved narko-curare-elektrostimulation. <i>Nordic Journal of Psychiatry</i> , 1979, 33, 9-14.	0.1	1
334	Giant Cell Arteritis, Temporal Arteritis and Polymyalgia Rheumatica. <i>Acta Medica Scandinavica</i> , 1977, 201, 207-213.	0.0	108
335	Treatment of Hookworm Anemia. <i>Scandinavian Journal of Infectious Diseases</i> , 1971, 3, 65-69.	1.5	3
336	Neutralizing antibodies directed against biologic agents to treat multiple sclerosis. , 0, , 287-299.		0
337	Intravenous immunoglobulin to treat multiple sclerosis. , 0, , 444-453.		0